Aurinia Pharmaceuticals Inc
AUPH
Market Cap$1.11B
Close$
$7.01
14.3% downside
Current Fair Value
14.3% downsideOvervalued by 14.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.11 Billion |
|---|---|
| Enterprise Value | $1.13 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $0.04 |
| Beta | 1.16 |
| Outstanding Shares | 138,917,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 28.52 |
|---|---|
| PEG | -8.99 |
| Price to Sales | 8.18 |
| Price to Book Ratio | 4.09 |
| Enterprise Value to Revenue | 4.83 |
| Enterprise Value to EBIT | 32.72 |
| Enterprise Value to Net Income | 28 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.25 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Aurinia Pharmaceuticals Inc
CEO: Peter Greenleaf